Thyroid hormone use and bone mineral density in elderly women. Although research data has not conclusively proven that deep venous thrombosis risk is higher in women on HRT, FDA product labeling states that present or a history of thromboembolism is a contraindication to estrogen. Patient specific decisions about hormone replacement therapy in postmenopausal women. Only those women without risk factors for CHD or hip fracture, but who have two first-degree relatives with breast cancer should not receive hormone therapy. However, women who receive estrogen should see their clinician annually and should therefore be receiving screening mammography and a breast examination.
Cancer surveillance leads to early diagnosis when breast cancer is curable.
This increased risk must be balanced against the cardiovascular benefit of estrogen use. Women should be reminded that cardiovascular disease, not breast cancer, is the leading cause of death of postmenopausal women. Sands R, Studd J. Exogenous androgens in postmenopausal women. Fluoride Stimulates bone formation by stimulating osteoblastic proliferation Initial trials with fluoride increased bone density but the bone formed was poorly mineralized. A slow-release formulation shows promise in decreasing vertebral fracture rate without causing mineralization defects.